Protocol Summary		Back To Search Instructions
Protocol No.	2083GCCC	Principal Investigator	Mehra, Ranee
Phase	Phase II
Title	2083GCCC: Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma
Description	A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Treatment	Experimental: Goserelin Acetate + Pembrolizumab Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV Interventions: Drug: Goserelin Acetate Drug: Pembrolizumab
Key Eligibility	For more information on eligibility visit clinicaltrials.gov and search NCT03942653
Applicable Disease Sites	H&N
Status	Open
Treatment Type	Treatment
ClinicalTrials.gov	http://www.clinicaltrials.gov/ct2/show/NCT03942653
Contact	Rehan Khan	Phone: Pager: Email:Rehan.Khan@umm.edu

Back to Protocol Listing